Humira SC (adalimumab/hyaluronidase) / AbbVie, Halozyme - LARVOL DELTA

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Takeda | N=100 ➔ 50

Enrollment change • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) - P1 | N=160 | Active, not recruiting | Sponsor: Prestige Biopharma Limited | Recruiting ➔ Active, not recruiting | N=324 ➔ 160 | Trial completion date: May 2026 ➔ Aug 2027 | Trial primary completion date: Feb 2026 ➔ Jun 2027

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date

Successful treatment of refractory classic juvenile pityriasis rubra pilaris with adalimumab in a 4-year-old girl: a case report. (PubMed, Front Immunol) - "Our findings support the potential role of TNF-α inhibitors as an effective alternative for severe pediatric PRP unresponsive to conventional therapies. Further prospective controlled trials are warranted to validate the long-term safety profile and optimize the dosage regimen for young pediatric populations."

Journal • Dermatology • Dermatopathology • Immunology • Inflammation • Mood Disorders • Oncology • Pediatrics • Pruritus • Psoriasis • Psychiatry

SELECT- SWITCH: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - P3 | N=487 | Completed | Sponsor: AbbVie | Active, not recruiting ➔ Completed

Adverse events • Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

BIMEKIZUMAB TIME TO MEANINGFUL IMPROVEMENTS IN CLINICAL AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A POST HOC ANALYSIS OF TWO POOLED PHASE 3 STUDIES (EULAR 2026) - P3 | "BE OPTIMAL included a subcutaneous adalimumab 40 mg Q2W reference arm; data not reported here. Conclusions BKZ treatment was associated with rapid, clinically meaningful improvements across joint, skin and PRO measures; many responses were achieved within 8–16 weeks and sustained through 3 years in patients with active PsA who were bDMARD-naïve or TNFi-IR, though interpretation should consider the post hoc design and potential confounding factors. Notably, patients receiving BKZ treatment reported meeting improvements for pain (Pain30) and physical function (HAQ‑DI MCID) within approximately 8-12 weeks, highlighting the potential benefit of BKZ for prompt patient well-being enhancement."

Clinical • P3 data • Patient reported outcomes • Retrospective data • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

BIMEKIZUMAB TREATMENT RESULTED IN RAPID RESPONSE THAT WAS ASSOCIATED WITH CLINICALLY IMPORTANT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS (EULAR 2026) - P3 | "BE OPTIMAL also included a reference arm of subcutaneous adalimumab 40 mg Q2W (data not shown). Conclusions Patients with PsA treated with BKZ who achieved ACR50 or SJC=0 responders at Week 16 demonstrated greater and sustained improvements in pain, fatigue and disease impact over 3 years, both in bDMARD-naïve patients and those who had had prior TNFi-IR. While interpretation should consider the post hoc design and potential confounding factors, such as Pain VAS being a component of the ACR response, these data support that early and rapid clinical response may be an indicator of long-term improvements in PROs, which furthers our understanding of the importance of timely intervention in PsA management."

Clinical • Patient reported outcomes • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Prolonging dosing interval of adalimumab in patients with non-infectious uveitis: an open-label, non-inferiority, randomized clinical trial (ChiCTR) - P=N/A | N=250 | Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Peking Union Medical College Hospital, Ch

Head-to-Head • New trial • Ocular Inflammation • Ophthalmology • Uveitis

Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). (PubMed, Rheumatol Ther) - P | "In this real-world Canadian study, switching from adalimumab RP or alternative biosimilar to AVT02 was associated with reductions in ISP and reactions while maintaining high adherence, patient satisfaction, quality of life, and disease control across multiple indications."

Journal • Ankylosing Spondylitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hidradenitis Suppurativa • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis

Chronic nonbacterial osteomyelitis: a typical case and review. (PubMed, Front Pediatr) - "Treatment included NSAIDs, intravenous antibiotics, and oral medications such as diclofenac sodium, naproxen, methotrexate, and calcitriol...After escalation to intravenous pamidronate and subcutaneous adalimumab, the patient achieved sustained clinical remission...This case underscores the complexity of diagnosing and managing CNO, highlighting the need for a multidisciplinary approach. Further research is essential to establish standardized diagnostic criteria and optimize treatment strategies for this rare condition."

Journal • Review • Infectious Disease • Inflammation • Oncology • Orthopedics • Pain

Real-world use of biologics for non-systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database. (PubMed, Mod Rheumatol) - "Our study described the real-world usage of biologics for nsJIA in Japan."

Journal • Real-world evidence • Ankylosing Spondylitis • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis. (PubMed, Adv Ther) - "The current NMA integrating recently updated phase 3 data in CD indicated that no single treatment significantly outperformed others in achieving clinical remission and endoscopic response, although SC infliximab 120 mg q.2.w exhibited highest numerical efficacy as both a first-line and second-or-later-line maintenance treatment in adult patients with moderate-to-severe CD."

Journal • Retrospective data • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trial. (PubMed, Am J Ophthalmol) - P2 | "Adalimumab and tocilizumab show comparable efficacy in active, refractory NIU, whereas anakinra was ineffective."

Journal • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis • Vasculitis

Give weekly adalimumab a chance before discontinuing it: a retrospective clinical and pharmacokinetic analysis in pediatric rheumatology. (PubMed, Arthritis Res Ther) - "Weekly adalimumab administrations were safe and effective in controlling both articular and ocular inflammation. In cases where the disease is poorly controlled with regular biweekly administrations, we encourage escalating adalimumab treatment to weekly administration before adding other therapies or switching to different biologics."

Journal • PK/PD data • Retrospective data • Idiopathic Arthritis • Immunology • Inflammation • Inflammatory Arthritis • Ocular Inflammation • Ophthalmology • Pediatrics • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Uveitis

Comment on 'Intravitreal versus Subcutaneous Adalimumab in Active Non-Infectious Uveitis: A Randomized Non-Inferiority Trial'. (PubMed, Ocul Immunol Inflamm) - "report that intravitreal adalimumab is non-inferior to subcutaneous administration for controlling intraocular inflammation in non-infectious uveitis. This correspondence discusses the broader clinical implications of these findings, highlighting cost considerations, the need to balance systemic safety with local procedural risks, and the importance of patient-reported outcomes and extended dosing regimens to enhance treatment acceptability."

Head-to-Head • Journal • Inflammation • Ocular Inflammation • Ophthalmology • Uveitis

SELECT- SWITCH: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - P3 | N=487 | Active, not recruiting | Sponsor: AbbVie | Trial primary completion date: Aug 2025 ➔ Jul 2026

Adverse events • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP

Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies (ACR Convergence 2025) - P3 | "BE OPTIMAL included a reference arm (sc adalimumab 40 mg Q2W; data not shown). BKZ treatment resulted in clinically meaningful improvements in PsAID-12 scores across physical, social and psychological domains in pts with active PsA, indicating reduced disease impact. Improvements were sustained to 3 yrs and consistent responses were seen in pts who were bDMARD-naive or had TNFi-IR."

Clinical • P3 data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

INTRAVENOUS INFLIXIMAB, SUBCUTANEOUS INFLIXIMAB AND SUBCUTANEOUS ADALIMUMAB AS "TOP-DOWN" TREATMENT FROM DIAGNOSIS, ARE ALL MORE EFFECTIVE, SAFER AND LESS COSTLY THAN CONVENTIONAL 'STEP-UP' CARE FOR PATIENTS WITH ACTIVE CROHN'S DISEASE (UEGW 2025) - "This health economic analysis demonstrates that early effective "top-down" treatment with anti-TNF therapy from diagnosis results in lower healthcare resource use compared to an "accelerated step-up" strategy. The economic benefits align with improved clinical outcomes, as early, effective treatment better controls inflammation. Patients experience longer periods in remission, fewer disease-related flares, and enhanced quality of life."

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Crohn's disease-like perianastomotic ulcerations after neonatal necrotizing enterocolitis surgery: a case of successful anti-TNF therapy. (PubMed, BMC Pediatr) - "Early anti-TNF therapy induced rapid and sustained remission in a pediatric patient with DPAU, reinforcing the mechanism that TNF-α-driven inflammation underlies disease pathogenesis. While promising, these findings require validation in larger cohorts. Individualized therapeutic decisions should weigh the risks of recurrence, cost, and long-term biologic safety."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Inflammatory Bowel Disease • Oncology • Pain • Pediatrics

Disseminated necrobiosis lipoidica with sustained therapeutic response to adalimumab and dapsone (EADV 2025) - "Other therapeutic modalities include hydroxychloroquine, cyclosporine, and phototherapy (PUVA), with surgical approaches reserved for localized ulcerated cases. The diagnosis of necrobiosis lipoidica is based on clinicopathological correlation. Clinically, it presents with sclerotic erythematous halos, atrophic pink-yellow centers, and telangiectasias. Histopathologically, there is degeneration of dermal collagen, lymphohistiocytic inflammatory infiltrate, and occasionally, palisading granulomas."

Dermatology • Diabetes • Immunology • Metabolic Disorders • Primary Immunodeficiency

Bullous pyoderma gangrenosum successfully treated with adalimumab: a case report (EADV 2025) - "The patient received intravenous methylprednisolone (40 mg/day, 1 week), human immunoglobulin (20 g/day, 3 days), and doxycycline (0.1 g/day, 1 week) with minimal improvement (Fig. Infectious diseases, vasculitis, and malignancies were excluded through clinical, histopathological, and lab evaluations. Adalimumab and low-dose glucocorticoids achieved rapid disease control and ulcer healing."

Case report • Clinical • Infectious Disease • Pyoderma Gangrenosum • Vasculitis • CXCL8 • IL15 • IL17A

Real-world use of biologics for systemic juvenile idiopathic arthritis: information from a Japanese hospital claims database. (PubMed, Mod Rheumatol) - "Our study described the real-world usage of biologics for sJIA in Japan."

Journal • Real-world evidence • Idiopathic Arthritis • Immunology • Oncology • Rheumatology

Treating apalutamide-induced toxic epidermal necrolysis with adalimumab and baricitinib in a patient with prostate cancer (EADV 2025) - "A multidisciplinary therapeutic strategy was instituted comprising high-dose intravenous immunoglobulin (20 g/day) for immunomodulation, pulse methylprednisolone (80 mg IV twice daily) as the initial anti-inflammatory intervention, subcutaneous adalimumab (80 mg weekly) for targeted TNF-α blockade, and oral baricitinib (2 mg twice daily) to inhibit JAK1/2-mediated signaling pathways. This case demonstrates TNF-α inhibitor/JAKi combination therapy effectively manages refractory TEN in cancer patients, through synergistic immunomodulation and neutralizing cytokine storms. The regimen achieved rapid re-epithelialization with reduced steroid dependence, addressing malignancy-associated immune dysregulation. Large-scale clinical studies are still needed to explore the clinical potential of TNF-α inhibitor and JAKi in cancer patients with TEN."

Clinical • Genito-urinary Cancer • Immunology • Oncology • Prostate Cancer • Solid Tumor • Steven-Johnson Syndrome

A RARE CAUSE OF SEVERE UPPER AIRWAY OBSTRUCTION-A DIAGNOSTIC DILEMMA AND MANAGEMENT CHALLENGE. (MTS 2025) - "Despite aggressive immunosuppression with intravenous methylprednisolone, methotrexate, cyclophosphamide, and mycophenolate mofetil, she experienced disease progression complicated by steroid toxicity and recurrent infections. Subcutaneous adalimumab was initiated with partial response...Conclusion RPC should be considered in pediatric patients with recurrent upper airway obstruction. Early diagnosis and a multidisciplinary approach are crucial to prevent severe complications and manage disease progression effectively."

Conjunctivitis • Immunology • Infectious Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective study. (PubMed, Rheumatology (Oxford)) - "In this study, we confirm that infliximab and adalimumab are both effective in TAK, without significant differences in the risk of relapse and revascularizations."

Journal • Retrospective data • Vasculitis

Intravitreal versus Subcutaneous Adalimumab in Active Non-Infectious Uveitis: A Randomized Non-Inferiority Trial. (PubMed, Ocul Immunol Inflamm) - "Secondary outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), fluorescein angiography (FA) score, and oral prednisone dose. A total of 23 patients (43 eyes) were randomized into the SCA (n = 12) or IVA (n = 11) treatment group. No serious systemic or ocular adverse events (AE) were observed. SCA resulted in a higher number of non-serious systemic AE (21) compared to IVA (5). IVA was non-inferior to SCA in treating active NIU and resulted in fewer systemic adverse events."

Head-to-Head • Journal • Ocular Inflammation • Ophthalmology • Uveitis